OSRH

OSR Holdings, Inc. Common Stock
OSRH
Market cap $28.3M

1.47 USD

-0.25

14.53%

At close Apr 2, 4:00 PM EDT

After hours

1.50

+0.03

2.04%

1 day

-14.53%

5 days

-50.67%

1 month

-43.46%

3 months

-87.05%

6 months

-86.54%

Year to date

-87.05%

1 year

-86.22%

5 years

-85.45%

10 years

-85.45%

About: OSR Holdings Inc is a healthcare company, dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of and potentially transformative therapies and healthcare solutions.

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,398 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

38.18% less ownership

Funds ownership: 38.53% [Q3] → 0.35% (-38.18%) [Q4]

77% less funds holding

Funds holding: 13 [Q3] → 3 (-10) [Q4]

99% less capital invested

Capital invested by funds: $16.9M [Q3] → $164K (-$16.8M) [Q4]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for OSRH.

See Analyst Rankings

Financial journalist opinion

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland , March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025 Under the symbol "OSRH" SEOUL, South Korea , Feb. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the "Company")) and OSR Holdings Co., Ltd. ("OSR") announced today the completion of their business combination (the "Business Combination").

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

See News Rankings

Charts implemented using Lightweight Charts™